title: Postoperative treatment with low molecular weight heparin after right heart assist for coronary artery bypass grafting.
abstract: Right heart assist (RHA) was used for coronary artery bypass grafting (CABG). We explored the affection of the coagulation system during surgery and evaluated two different antithrombotic treatments postoperatively. The pilot study comprised 14 patients. During surgery activated clotting time (ACT) was kept > 200 sec. By random the patients were selected to different postoperative treatments. The control group received acetyl salicylic acid (ASA) 150 mg daily, the intervention group received ASA 150 mg daily and Low Molecular Weight Heparin (LMWH) 5000 IU x2 for three days. Serum levels of prothrombin fragment 1 and 2 (F 1 + 2), plasmin-antiplasmin product (PAP), anti-Xa activity and functional antithrombin (ATIII) were measured. During surgery there was no increase of F 1 + 2 or PAP. After protamin was administered there was a significant increase of F 1 + 2 but not in PAP during the next 6 hours. Postoperative antithrombotic treatment with LMWH seems to normalise F1 + 2 while ASA does not. ACT level > 200 sec. seems sufficient for RHA-CABG surgery. Fibrinolytic agents are not necessary. It seems that postoperative LMWH treatment prevents increased thrombin formation. General recommendations with respect to antithrombotic treatment beyond ASA can not be made based on study.
authors.affiliation: Department of Cardiothoracic Surgery, H:S Rigshospitalet, Copenhagen University Hospital, Denmark. phughes@pc.dk
authors.forename: P
authors.initials: P
authors.lastname: Hughes
authors.forename: J M
authors.initials: JM
authors.lastname: Hasenkam
authors.forename: I K
authors.initials: IK
authors.lastname: Severinsen
authors.forename: D A
authors.initials: DA
authors.lastname: Steinbrüchel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000188:drug therapy* / Q000601:surgery; D000925:Anticoagulants / Q000008:administration & dosage*; D000933:Antifibrinolytic Agents / Q000097:blood; D001241:Aspirin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass; D005260:Female; D006353:Heart-Assist Devices; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D010865:Pilot Projects; D011516:Prothrombin; D014914:Whole Blood Coagulation Time
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010446:Peptide Fragments; C045879:prothrombin fragment 1.2; D011516:Prothrombin; D001241:Aspirin